Key Takeaways
- • Canary Capital has proposed a staked Injective (INJ) exchange-traded fund under the ticker INJS, to be listed on Cboe BZX, with at least 90% of holdings committed to staking.
- • The U.S. Securities and Exchange Commission has opened a 21-day public comment period on the proposed Canary staked INJ ETF, the next procedural step in the review.
- • If approved, the fund would give retail and institutional investors direct exposure to the spot price of INJ, combined with staking yield, through a regulated investment vehicle.
- • Injective's CEO has said a U.S. INJ ETF is coming sooner than expected, according to publisher reporting.
Summary
Canary Capital has filed for a staked Injective ETF, which would track the native token of the Injective blockchain and trade on Cboe BZX under the proposed ticker INJS. According to publisher reporting, the fund would commit at least 90% of its holdings to staking. Staking adds operational complexity relative to a spot-only product, but it also allows the fund to earn protocol rewards on top of any change in the token's price.
The U.S. SEC has opened a public comment period on the proposal, providing 21 days for stakeholders to submit views on Canary's application. The filing is part of a broader wave of crypto ETF applications from Canary, which has continued to expand its filings across digital assets.
Publisher coverage notes that two U.S. ETFs tied to INJ are advancing, and that Injective's CEO has said a U.S. INJ ETF is arriving sooner than expected. The INJ chart has reportedly been rejected at the same price level four times, a technical observation that underscores the token's volatility. Investors evaluating the product would need to weigh that price behavior alongside staking-related risks, including validator performance and lock-up considerations inherent to proof-of-stake networks.
Approval would give institutional allocators a regulated route to INJ exposure without direct custody of the token, a development that could broaden access to a segment of the market that has so far been reached mainly through native tokens and offshore products.
The U.S. SEC has opened a public comment period on the proposal, providing 21 days for stakeholders to submit views on Canary's application. The filing is part of a broader wave of crypto ETF applications from Canary, which has continued to expand its filings across digital assets.
Publisher coverage notes that two U.S. ETFs tied to INJ are advancing, and that Injective's CEO has said a U.S. INJ ETF is arriving sooner than expected. The INJ chart has reportedly been rejected at the same price level four times, a technical observation that underscores the token's volatility. Investors evaluating the product would need to weigh that price behavior alongside staking-related risks, including validator performance and lock-up considerations inherent to proof-of-stake networks.
Approval would give institutional allocators a regulated route to INJ exposure without direct custody of the token, a development that could broaden access to a segment of the market that has so far been reached mainly through native tokens and offshore products.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.